Systemic Corticosteroids in Patients With Bronchial Asthma: A Real-Life Study.

IF 6.1 3区 医学 Q1 ALLERGY Journal of Investigational Allergology and Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2021-04-15 DOI:10.18176/jiaci.0765
J L Izquierdo, C Almonacid, C Campos, D Morena, M Benavent, D González-de-Olano, J M Rodríguez
{"title":"Systemic Corticosteroids in Patients With Bronchial Asthma: A Real-Life Study.","authors":"J L Izquierdo, C Almonacid, C Campos, D Morena, M Benavent, D González-de-Olano, J M Rodríguez","doi":"10.18176/jiaci.0765","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of the present study was to determine the use of systemic corticosteroids (SCs) in patients with bronchial asthma using big data analysis.</p><p><strong>Methods: </strong>We performed an observational, retrospective, noninterventional study based on secondary data captured from free text in the electronic health records. This study was performed based on data from the regional health service of Castille-La Mancha (SESCAM), Spain. We performed the analysis using big data and artificial intelligence via Savana® Manager version 3.0.</p><p><strong>Results: </strong>During the study period, 103 667 patients were diagnosed with and treated for asthma at different care levels. The search was restricted to patients aged 10 to 90 years (mean age, 43.5 [95%CI, 43.4-43.7] years). Of these, 59.8% were women. SCs were taken for treatment of asthma by 58 745 patients at some point during the study period. These patients were older, with a higher prevalence of hypertension, dyslipidemia, diabetes, obesity, depression, and hiatus hernia. SCs are used frequently in the general population with asthma (31.4% in 2015 and 39.6% in 2019). SCs were prescribed mainly in primary care (59%), allergy (13%), and pulmonology (20%). The frequency of prescription of SCs had a direct impact on the main associated adverse effects.</p><p><strong>Conclusion: </strong>In clinical practice, SCs are frequently prescribed to patients with asthma, especially in primary care. Use of SCs is associated with a greater number of adverse events. It is necessary to implement measures to reduce prescription of SCs to patients with asthma, especially in primary care.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"30-38"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigational Allergology and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18176/jiaci.0765","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The objective of the present study was to determine the use of systemic corticosteroids (SCs) in patients with bronchial asthma using big data analysis.

Methods: We performed an observational, retrospective, noninterventional study based on secondary data captured from free text in the electronic health records. This study was performed based on data from the regional health service of Castille-La Mancha (SESCAM), Spain. We performed the analysis using big data and artificial intelligence via Savana® Manager version 3.0.

Results: During the study period, 103 667 patients were diagnosed with and treated for asthma at different care levels. The search was restricted to patients aged 10 to 90 years (mean age, 43.5 [95%CI, 43.4-43.7] years). Of these, 59.8% were women. SCs were taken for treatment of asthma by 58 745 patients at some point during the study period. These patients were older, with a higher prevalence of hypertension, dyslipidemia, diabetes, obesity, depression, and hiatus hernia. SCs are used frequently in the general population with asthma (31.4% in 2015 and 39.6% in 2019). SCs were prescribed mainly in primary care (59%), allergy (13%), and pulmonology (20%). The frequency of prescription of SCs had a direct impact on the main associated adverse effects.

Conclusion: In clinical practice, SCs are frequently prescribed to patients with asthma, especially in primary care. Use of SCs is associated with a greater number of adverse events. It is necessary to implement measures to reduce prescription of SCs to patients with asthma, especially in primary care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
支气管哮喘患者的全身皮质类固醇治疗:一项真实生活研究
研究目的本研究的目的是利用大数据分析确定支气管哮喘患者使用全身性皮质类固醇(SC)的情况:我们根据电子健康记录中的自由文本获取的二手数据,开展了一项观察性、回顾性、非干预性研究。这项研究基于西班牙卡斯蒂利亚-拉曼恰地区卫生服务机构(SESCAM)的数据。我们通过 Savana® Manager 3.0 版使用大数据和人工智能进行了分析:在研究期间,共有 103 667 名哮喘患者在不同级别的医疗机构接受了诊断和治疗。搜索对象仅限于 10 至 90 岁的患者(平均年龄为 43.5 [95%CI, 43.4-43.7] 岁)。其中 59.8% 为女性。在研究期间,有 58 745 名患者曾在某段时间服用过 SCs 治疗哮喘。这些患者年龄较大,高血压、血脂异常、糖尿病、肥胖、抑郁和食道裂孔疝的发病率较高。普通哮喘患者经常使用镇静剂(2015 年为 31.4%,2019 年为 39.6%)。开具 SCs 处方的主要是初级保健科(59%)、过敏科(13%)和肺病科(20%)。SCs处方的频率对主要相关不良反应有直接影响:结论:在临床实践中,哮喘患者,尤其是初级医疗机构的哮喘患者经常会被处方SCs。结论:在临床实践中,哮喘患者尤其是基层医疗机构的哮喘患者经常会被处方解痉剂。有必要采取措施减少哮喘患者(尤其是基层医疗机构的哮喘患者)的SCs处方。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.10
自引率
9.70%
发文量
135
审稿时长
6-12 weeks
期刊介绍: The Journal of Investigational Allergology and Clinical Immunology (J Investig Allergol Clin Immunol) provides an attractive and very active forum for basic and clinical research in allergology and clinical immunology.Journal of Investigational Allergology and Clinical Immunology publishes original works, reviews, short communications and opinions.
期刊最新文献
Obese Asthma Syndrome: Multiple Inflammatory Patterns and A Key Solution. Reduced Prostaglandin D2 Production by Airway Fibroblasts in Nonsteroidal Anti-inflammatory Drug- Exacerbated Airway Disease. Sensitization to Pru p 7 in Peach-Allergic Patients Sensitized to Pru p 3 in Areas of High Exposure to Cypress Pollen. Anaphylaxis Induced by Milk Thistle (Silybum marianum) Seed Ingestion: A Case Report. Revisited the Impact of Misdiagnosed Drug Hypersensitivity in Hospitalized Patients: A 10-Year Perspective.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1